Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest Chinese Drug Coverage Comes With Steep Price Cuts, Caveats

But Bigger Volumes Await

Executive Summary

November negotiations in China over the prices of 67 new drugs have resulted in record price cuts, averaging around 62% overall and 65% for anti-tumor products. But the sting is alleviated by the prospect of substantial volume increases.

You may also be interested in...



Balancing Act: Orphan Drug Makers Slash Prices In China As New Mechanism Allures

From Biogen to Takeda, multinationals have been cutting prices in China in a bid to seize the emerging market for rare disease treatments, as Beijing strives to expand market access.

Rare Chance Or Passing Opportunity: China Expands Orphan Drug Coverage With Steep Price Cuts

Latest national medical insurance negotiations results show orphan drugs are covered, but Biogen’s Spinraza gets a 95% price cut. Getting coverage, rather holding out for a high price, really makes more sense in the emerging Chinese market for rare disease drugs, industry observers say.

Chinese Biotechs Raise $212m Through Major VC/PE Deals in November

Leading the group were Trinomab Biotech, which develops antibodies for infectious diseases, and cell and gene developers BRL Medicine and XellSmart.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC145531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel